FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to biochemistry. Methods include the application of highly specific and highly effective antibodies, which specifically identify and bind specific epitopes from the range of β-amyloid proteins. The invention can be used for the eye diseases, associated with pathological impairment/changes of the visual system tissues, especially associated with amyloid-beta-associated pathological impairment/changes in the visual system tissues.
EFFECT: described are methods of diagnosing an eye disease, diagnostics or detection of a predisposition to the eye disease, monitoring of a minimal residual eye disease.
44 cl, 20 dwg, 7 tbl, 18 ex
Title | Year | Author | Number |
---|---|---|---|
USING ANTI-AMYLOID BETA ANTIBODY IN OPHTHALMIC DISEASES | 2008 |
|
RU2542967C2 |
HUMANISED ANTIBODY | 2008 |
|
RU2538709C2 |
HUMANISED ANTIBODIES TO AMYLOID BETA | 2008 |
|
RU2567151C2 |
HUMANISED ANTIBODY TO BETA AMYLOID | 2007 |
|
RU2498999C2 |
HUMANIZED ANTIBODY TO BETA AMYLOID | 2013 |
|
RU2668161C2 |
USING ANTI-AMYLOID BETA ANTIBODY IN OPHTHALMIC DISEASES | 2008 |
|
RU2604181C2 |
USE OF ANTI-BETA AMYLOID ANTIBODY IN OPHTHALMIC DISEASES | 2008 |
|
RU2482876C2 |
HUMANIZED TAU-ANTIBODY | 2013 |
|
RU2644242C2 |
SAFE AND FUNCTIONAL HUMANIZED ANTIBODIES | 2011 |
|
RU2607368C2 |
METHODS OF TREATING ALZHEIMER'S DISEASE | 2015 |
|
RU2720468C2 |
Authors
Dates
2015-12-20—Published
2008-10-03—Filed